BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Landslides triggered by heavy rainfall kill at least 20 people in Tanzania - 2This St Nick Truly Can Advise How To Drink And Hack Your Headache
- 3Medtronic has 'significant firepower' for multiple acquisitions, executives say
- 4Web designers for Independent ventures
- 5These Are the Journalists Israel Has Killed Since the Start of the Iran War
- How did life begin on Earth? New experiments support 'RNA world' hypothesis
- 6 Useful Home Espresso Machines
- Fuel Price Spike Drives Surge in Used EV Sales in Europe
- Manual for Tracking down Spending plan Agreeable Travel Objections
- FDA updates risk classification for voluntary shredded cheese recall
- Israel and Lebanon's Hezbollah continue to trade attacks
- 5 Great Home Remodel Administrations With Green Arrangements In 2024
- 'It's doing badly': Fears grow for whale stuck off Germany's coast
- Data centers in space: Will 2027 really be the year AI goes to orbit?
